Medical Health & Life Science Research News

Checkpoint inhibitors market worth $21.25 billion by 2021

Checkpoint inhibitors market worth $21.25 billion by 2021

The Global Checkpoint Inhibitors Market was worth USD 6.08 billion in 2016 and is expected to reach USD 21.25 billion by 2021 with a CAGR of 28.4 %.

- Advertising -

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells.

T-cells launches an attack when it detects infected or Cancerous.

- Advertising -

Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack.

Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.

Browse market data tables and in-depth TOC of the Global Checkpoint Inhibitors Industry to 2021 @ www.marketdataforecast.com/market-…tors-market-2177/

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.

Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, others.

Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market.

However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.

Free sample of the report is available @ www.marketdataforecast.com/market-…77/request-sample

Geographically, market is further segmented into Asia-Pacific, Europe, Latin America, Middle east and Africa and North America. North America dominates the global market owing the relatively high clinical trials and funding available in this region.

Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.

Some of the key players in the checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

Enquire about report at www.marketdataforecast.com/market-…rket-2177/inquire

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...